Impact of BAP1 mutational status on immunotherapy outcomes in advanced malignant pleural mesothelioma: A single institution experience.

• DOI: 10.1200/jco.2023.41.16_suppl.e20537
• Publication Date: 2023-06-04T16:15:51Z
• Authors: Olisaemeka Ogbue; Serhan Unlu; Sharmeen Sorathia; Abdel Rahman Nanah; Fatima Abdeljaleel; Abdo S. Haddad; Hamed Daw
• Keywords: BAP1; Pemetrexed; Carboplatin; Targeted Therapy

e20537 Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor of mesothelial cells usually diagnosed at advanced stages with dismal prognosis. Most patients progress after 1 st line systemic chemotherapy. In the last decade, single or dual agent immune checkpoint inhibitor (ICI) therapy has emerged as therapeutic option. BAP1 commonly mutated suppressor gene in MPM that been shown to correlate negatively survival other solid tumors. We sought determine impact mutation on outcomes ICIs when used second therapy. Methods: retrospectively reviewed cohort who received Cleveland Clinic foundation between 2017-2022. Patients must have progressed chemotherapy prior ICI. then compared oncologic ICI based mutational status Next-Generation Sequencing (NGS). End points interest were overall response rate (ORR) progression free (PFS) while ICIs. Results: There total 43 following pemetrexed/carboplatin (Median age 74 years, IQR 66-81, range 57-92) male predominance (M:F ratio 39:4). Histologies included- 58% epithelioid, 28% sarcomatoid 14% mixed/biphasic histology. Single nivolumab pembrolizumab was 65%. Median follow up 3 months. NGS detected 16%. Other genes included CDKN2A- 7%, BRAF- 5%, MTAP 2% PTEN 2%. baseline characteristics wild type (WT) (MT) groups. diagnosis similar vs 70 years (0.3347) no significant differences either asbestos smoking exposure (Table 1). An analysis revealed an ORR 33% (36% 29% respectively [p = 0.9]). PFS both groups - 4 months [95% CI, 3-NA] for WT 2-18] MT group. Conclusions: had prognostic significance rates disease our patients. The identification predictive biomarkers immunotherapy area unmet clinical need. [Table: see text]